Role of peroxiredoxin i in rectal cancer and related to p53 status

Miao Fen Chen, Kuan Der Lee, Chung Hung Yeh, Wen Cheng Chen, Wen Shih Huang, Chih Chien Chin, Paul Yang Lin, Jeng Yi Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavenge reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.

Original languageEnglish
Pages (from-to)868-878
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume78
Issue number3
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Peroxiredoxins
Rectal Neoplasms
cancer
tumors
prognosis
staining
membranes
biomarkers
animals
manipulators
therapy
deoxyribonucleic acid
Staining and Labeling
damage
Immunochemistry
Neoplasms
irradiation
Neoadjuvant Therapy
Membranes
Chemoradiotherapy

Keywords

  • p53 status
  • Peroxiredoxin I
  • radiation
  • rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research
  • Medicine(all)

Cite this

Role of peroxiredoxin i in rectal cancer and related to p53 status. / Chen, Miao Fen; Lee, Kuan Der; Yeh, Chung Hung; Chen, Wen Cheng; Huang, Wen Shih; Chin, Chih Chien; Lin, Paul Yang; Wang, Jeng Yi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 78, No. 3, 2010, p. 868-878.

Research output: Contribution to journalArticle

Chen, Miao Fen ; Lee, Kuan Der ; Yeh, Chung Hung ; Chen, Wen Cheng ; Huang, Wen Shih ; Chin, Chih Chien ; Lin, Paul Yang ; Wang, Jeng Yi. / Role of peroxiredoxin i in rectal cancer and related to p53 status. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 78, No. 3. pp. 868-878.
@article{b38848d010bd491094c0ac4c4513ebe9,
title = "Role of peroxiredoxin i in rectal cancer and related to p53 status",
abstract = "Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavenge reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.",
keywords = "p53 status, Peroxiredoxin I, radiation, rectal cancer",
author = "Chen, {Miao Fen} and Lee, {Kuan Der} and Yeh, {Chung Hung} and Chen, {Wen Cheng} and Huang, {Wen Shih} and Chin, {Chih Chien} and Lin, {Paul Yang} and Wang, {Jeng Yi}",
year = "2010",
doi = "10.1016/j.ijrobp.2010.05.025",
language = "English",
volume = "78",
pages = "868--878",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Role of peroxiredoxin i in rectal cancer and related to p53 status

AU - Chen, Miao Fen

AU - Lee, Kuan Der

AU - Yeh, Chung Hung

AU - Chen, Wen Cheng

AU - Huang, Wen Shih

AU - Chin, Chih Chien

AU - Lin, Paul Yang

AU - Wang, Jeng Yi

PY - 2010

Y1 - 2010

N2 - Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavenge reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.

AB - Background: Neoadjuvant chemoradiotherapy is widely accepted for the treatment of localized rectal cancer. Although peroxiredoxin I (PrxI) and p53 have been implicated in carcinogenesis and cancer treatment, the role of PrxI and its interaction with p53 in the prognosis and treatment response of rectal cancer remain relatively unstudied. Methods and Materials: In the present study, we examined the levels of PrxI and p53 in rectal cancer patients using membrane arrays and compared them with normal population samples. To demonstrate the biologic changes after manipulation of PrxI expression, we established stable transfectants of HCT-116 (wild-type p53) and HT-29 (mutant p53) cells with a PrxI silencing vector. The predictive capacities of PrxI and p53 were also assessed by relating the immunohistochemical staining of a retrospective series of rectal cancer cases to the clinical outcome. Results: The membrane array and immunochemical staining data showed that PrxI, but not p53, was significantly associated with the tumor burden. Our immunochemistry findings further indicated that PrxI positivity was linked to a poor response to neoadjuvant therapy and worse survival. In cellular and animal experiments, the inhibition of PrxI significantly decreased tumor growth and sensitized the tumor to irradiation, as indicated by a lower capacity to scavenge reactive oxygen species and more extensive DNA damage. The p53 status might have contributed to the difference between HCT-116 and HT-29 after knockdown of PrxI. Conclusion: According to our data, the level of PrxI combined with the p53 status is relevant to the prognosis and the treatment response. We suggested that PrxI might be a new biomarker for rectal cancer.

KW - p53 status

KW - Peroxiredoxin I

KW - radiation

KW - rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=77957194152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957194152&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.05.025

DO - 10.1016/j.ijrobp.2010.05.025

M3 - Article

VL - 78

SP - 868

EP - 878

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -